From the analysis, we found that the most potent compounds for the six high-risk cancer patients were dactinomycin (RNA synthesis inhibitor); panobinostat (pan-HDAC inhibitor); dinaciclib (CDK1/2/5/9 inhibitor); SN-38 and GENZ-644282 (DNA topoisomerase I inhibitors); carfilzomib (proteasome inhibitor) and ceritinib (ALK inhibitor) (Figs. 6B and EV5D). This evidence concerns the gene CDK1 and cancer.